UCB
UCBJYDrugs in Pipeline
90
Phase 3 Programs
63
Upcoming Catalysts
10
Next Catalyst
This month
Market Overview
Stock performance and key metrics
10 upcoming, 2 past
Brivaracetam Phase 3 Est. Readout
Primary completion for Brivaracetam trial (NCT04666610) in Childhood Absence Epilepsy
SourceStaccato alprazolam Phase 3 Est. Readout
Primary completion for Staccato alprazolam trial (NCT05077904) in Stereotypical Prolonged Seizures
Sourcefenfluramine Phase 3 Est. Readout
Primary completion for fenfluramine trial (NCT06118255) in Dravet Syndrome
Source7 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Brivaracetam (ucb 34714)
Epilepsy
SPM 927
Partial Seizures With or Without Secondary Generalization
Cimzia
Crohn Disease
Etanercept
Psoriasis
Certolizumab Pegol
Rheumatoid Arthritis
Brivaracetam
Epilepsy
Secukinumab
Chronic Plaque Psoriasis
levocetirizine dihydrochloride
Rhinitis
Ketotifen
Rhinitis, Allergic, Perennial
Lacosamide
Epilepsy
Bimekizumab
Chronic Plaque Psoriasis
Lacosamide 50 mg
Epilepsy
Carbamazepine
Epilepsy
Certolizumab Pegol (CZP) 200 mg
Rheumatoid Arthritis
fenfluramine
Dravet Syndrome
Brivaracetam 2.5 mg
Epilepsy
Romosozumab
Osteoporosis
zilucoplan (RA101495)
Generalized Myasthenia Gravis
Certolizumab pegol (CZP)
Crohn's Disease
DZP
Systemic Lupus Erythematosus
Levocetirizine 1.25 mg
Allergic Rhinitis
Brivaracetam (BRV)
Epilepsy
Levetiracetam (LEV)
Epilepsy
Antiepileptic drugs with market authorization available per country
Epilepsy
Staccato alprazolam
Stereotypical Prolonged Seizures
CZP 400 mg Q4W
Spondyloarthropathies
Brivaracetam oral solution
Childhood Absence Epilepsy
Carbamazepine Controlled Release (CBZ-CR)
Epilepsy
Keppra XR (Levetiracetam XR)
Epilepsy
Carbamazepine-Controlled Release (CBZ-CR)
Epilepsy
Cetirizine
Dermatitis
Levetiracetam 166 mg
Generalized Epilepsy
e-Device
Moderate and Severe Active Rheumatoid Arthritis
USL261
Epilepsy
Alprazolam orally disintegrating tablets
ANXIETY
PARCOPA
Parkinson's Disease
Brivaracetam Film-coated tablet
Childhood Absence Epilepsy
Levetiracetam 250 mg
Epilepsies, Partial
Certolizumab Pegol + Methotrexate (MTX)
Rheumatoid Arthritis
Kemstro
Multiple Sclerosis
Rozanolixizumab
Generalized Myasthenia Gravis
Levocetirizine
Rhinitis, Allergic, Seasonal
Rotigotine
Restless Legs Syndrome
CDP870
Arthritis, Rheumatoid
Zilucoplan
Generalized Myasthenia Gravis
SPM 929
Painful Diabetic Neuropathy
Certolizumab Pegol (CDP870)
Crohn's Disease
Levetiracetam
Epilepsy
Carbamazepine-Controlled Release
Epilepsy
CZP 200 mg Q2W
Arthritis, Psoriatic
Keppra® extended release formulation - XR
Epilepsy
L-dopa
Idiopathic Parkinson's Disease
Lasosamide Oral Solution
Epilepsy
SPM 962
Parkinson's Disease
Lacosamide Tablet
Epilepsy
Risankizumab
Psoriatic Arthritis
BRV 2.5 mg
Unverricht-Lundborg Disease
Epratuzumab
Systemic Lupus Erythematosus
Brivaracetam tablets
Epilepsy
certolizumab pegol (CDP870, CZP)
Crohn Disease
Keppra XR
Epilepsy
Lacosamide (200 mg/20 mL)
Epilepsy
Alprostadil (Prostaglandin E1)
Stage II Peripheral Arterial Occlusive Disease
Rotigotine Nasal Spray
Restless Legs Syndrome
UCB0022
Parkinson Disease
Lorazepam
Epilepsy
UCB1381
Atopic Dermatitis
CDP323
Relapsing Multiple Sclerosis
UCB7665
Thrombocytopenia
UCB0942
Highly Drug-resistant Focal Epilepsy
SPM927/Lacosamide
Painful Diabetic Neuropathy
Galvokimig
Atopic Dermatitis
Tocilizumab (Actemra or RoActemra)
Rheumatoid Arthritis
Seletracetam (UCB44212)
Epilepsy, Partial
Epratuzumab 400 mg
Systemic Lupus Erythematosus
UCB9741
Atopic Dermatitis
CDP6038
Arthritis
Olokizumab 60 mg
Rheumatoid Arthritis
ginisortamab
Advanced Solid Tumors
Levocetirizine drops
Rhinitis
Bepranemab
Alzheimer's Disease
Dapirolizumab pegol (DZP)
Systemic Lupus Erythematosus (SLE)
doxecitine and doxribtimine
Thymidine Kinase 2 Deficiency
Certolizumab Pegol (Cimzia®)
Psoriasis
SPM 936
Idiopathic Restless Leg Syndrome
Seletracetam (ucb 44212)
Epilepsy, Partial
Somatostatin UCB (drug)
Peptic Ulcer
UCB0599
Early-stage Parkinson's Disease
Padsevonil
Drug-resistant Epilepsy
Levocetirizine oral solution
Allergic Rhinitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Brivaracetam (ucb 34714) | Phase 3 | Epilepsy | - | - |
SPM 927 | Phase 3 | Partial Seizures With or Without Secondary Generalization | - | - |
Cimzia | Phase 3 | Crohn Disease | - | - |
Etanercept | Phase 3 | Psoriasis | - | - |
Certolizumab Pegol | Phase 3 | Rheumatoid Arthritis | - | - |
Brivaracetam | Phase 3 | Epilepsy | - | - |
Secukinumab | Phase 3 | Chronic Plaque Psoriasis | - | - |
levocetirizine dihydrochloride | Phase 3 | Rhinitis | - | - |
Ketotifen | Phase 3 | Rhinitis, Allergic, Perennial | - | - |
Lacosamide | Phase 3 | Epilepsy | - | - |
Bimekizumab | Phase 3 | Chronic Plaque Psoriasis | - | - |
Lacosamide 50 mg | Phase 3 | Epilepsy | - | - |
Carbamazepine | Phase 3 | Epilepsy | - | - |
Certolizumab Pegol (CZP) 200 mg | Phase 3 | Rheumatoid Arthritis | - | - |
fenfluramine | Phase 3 | Dravet Syndrome | - | - |
Brivaracetam 2.5 mg | Phase 3 | Epilepsy | - | - |
Romosozumab | Phase 3 | Osteoporosis | - | - |
zilucoplan (RA101495) | Phase 3 | Generalized Myasthenia Gravis | - | - |
Certolizumab pegol (CZP) | Phase 3 | Crohn's Disease | - | - |
DZP | Phase 3 | Systemic Lupus Erythematosus | - | - |
Levocetirizine 1.25 mg | Phase 3 | Allergic Rhinitis | - | - |
Brivaracetam (BRV) | Phase 3 | Epilepsy | - | - |
Levetiracetam (LEV) | Phase 3 | Epilepsy | - | - |
Antiepileptic drugs with market authorization available per country | Phase 3 | Epilepsy | - | - |
Staccato alprazolam | Phase 3 | Stereotypical Prolonged Seizures | - | - |
CZP 400 mg Q4W | Phase 3 | Spondyloarthropathies | - | - |
Brivaracetam oral solution | Phase 3 | Childhood Absence Epilepsy | - | - |
Carbamazepine Controlled Release (CBZ-CR) | Phase 3 | Epilepsy | - | - |
Keppra XR (Levetiracetam XR) | Phase 3 | Epilepsy | - | - |
Carbamazepine-Controlled Release (CBZ-CR) | Phase 3 | Epilepsy | - | - |
Cetirizine | Phase 3 | Dermatitis | - | - |
Levetiracetam 166 mg | Phase 3 | Generalized Epilepsy | - | - |
e-Device | Phase 3 | Moderate and Severe Active Rheumatoid Arthritis | - | - |
USL261 | Phase 3 | Epilepsy | - | - |
Alprazolam orally disintegrating tablets | Phase 3 | ANXIETY | - | - |
PARCOPA | Phase 3 | Parkinson's Disease | - | - |
Brivaracetam Film-coated tablet | Phase 3 | Childhood Absence Epilepsy | - | - |
Levetiracetam 250 mg | Phase 3 | Epilepsies, Partial | - | - |
Certolizumab Pegol + Methotrexate (MTX) | Phase 3 | Rheumatoid Arthritis | - | - |
Kemstro | Phase 3 | Multiple Sclerosis | - | - |
Rozanolixizumab | Phase 3 | Generalized Myasthenia Gravis | - | - |
Levocetirizine | Phase 3 | Rhinitis, Allergic, Seasonal | - | - |
Rotigotine | Phase 3 | Restless Legs Syndrome | - | - |
CDP870 | Phase 3 | Arthritis, Rheumatoid | - | - |
Zilucoplan | Phase 3 | Generalized Myasthenia Gravis | - | - |
SPM 929 | Phase 3 | Painful Diabetic Neuropathy | - | - |
Certolizumab Pegol (CDP870) | Phase 3 | Crohn's Disease | - | - |
Levetiracetam | Phase 3 | Epilepsy | - | - |
Carbamazepine-Controlled Release | Phase 3 | Epilepsy | - | - |
CZP 200 mg Q2W | Phase 3 | Arthritis, Psoriatic | - | - |
Keppra® extended release formulation - XR | Phase 3 | Epilepsy | - | - |
L-dopa | Phase 3 | Idiopathic Parkinson's Disease | - | - |
Lasosamide Oral Solution | Phase 3 | Epilepsy | - | - |
SPM 962 | Phase 3 | Parkinson's Disease | - | - |
Lacosamide Tablet | Phase 3 | Epilepsy | - | - |
Risankizumab | Phase 3 | Psoriatic Arthritis | - | - |
BRV 2.5 mg | Phase 3 | Unverricht-Lundborg Disease | - | - |
Epratuzumab | Phase 3 | Systemic Lupus Erythematosus | - | - |
Brivaracetam tablets | Phase 3 | Epilepsy | - | - |
certolizumab pegol (CDP870, CZP) | Phase 3 | Crohn Disease | - | - |
Keppra XR | Phase 3 | Epilepsy | - | - |
Lacosamide (200 mg/20 mL) | Phase 3 | Epilepsy | - | - |
Alprostadil (Prostaglandin E1) | Phase 3 | Stage II Peripheral Arterial Occlusive Disease | - | - |
Rotigotine Nasal Spray | Phase 2 | Restless Legs Syndrome | - | - |
UCB0022 | Phase 2 | Parkinson Disease | - | - |
Lorazepam | Phase 2 | Epilepsy | - | - |
UCB1381 | Phase 2 | Atopic Dermatitis | - | - |
CDP323 | Phase 2 | Relapsing Multiple Sclerosis | - | - |
UCB7665 | Phase 2 | Thrombocytopenia | - | - |
UCB0942 | Phase 2 | Highly Drug-resistant Focal Epilepsy | - | - |
SPM927/Lacosamide | Phase 2 | Painful Diabetic Neuropathy | - | - |
Galvokimig | Phase 2 | Atopic Dermatitis | - | - |
Tocilizumab (Actemra or RoActemra) | Phase 2 | Rheumatoid Arthritis | - | - |
Seletracetam (UCB44212) | Phase 2 | Epilepsy, Partial | - | - |
Epratuzumab 400 mg | Phase 2 | Systemic Lupus Erythematosus | - | - |
UCB9741 | Phase 2 | Atopic Dermatitis | - | - |
CDP6038 | Phase 2 | Arthritis | - | - |
Olokizumab 60 mg | Phase 2 | Rheumatoid Arthritis | - | - |
ginisortamab | Phase 2 | Advanced Solid Tumors | - | - |
Levocetirizine drops | Phase 2 | Rhinitis | - | - |
Bepranemab | Phase 2 | Alzheimer's Disease | - | - |
Dapirolizumab pegol (DZP) | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
doxecitine and doxribtimine | Phase 2 | Thymidine Kinase 2 Deficiency | - | - |
Certolizumab Pegol (Cimzia®) | Phase 2 | Psoriasis | - | - |
SPM 936 | Phase 2 | Idiopathic Restless Leg Syndrome | - | - |
Seletracetam (ucb 44212) | Phase 2 | Epilepsy, Partial | - | - |
Somatostatin UCB (drug) | Phase 2 | Peptic Ulcer | - | - |
UCB0599 | Phase 2 | Early-stage Parkinson's Disease | - | - |
Padsevonil | Phase 2 | Drug-resistant Epilepsy | - | - |
Levocetirizine oral solution | Phase 2 | Allergic Rhinitis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in UCB's drug pipeline?→
CatalystAlert tracks 90 drug candidates in UCB's (UCBJY) pipeline across Phase 3, Phase 2. Its lead program is Brivaracetam (ucb 34714) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is UCB's next FDA catalyst?→
UCB's (UCBJY) next tracked catalyst is a Phase 3 expected August 7, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track UCBJY biotech catalysts?→
Add UCBJY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow UCB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.